• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023
Recommend to a Colleague print
 

Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides

Download the slide deck

TOPICS: Library, MS
Recommend to a Colleague

Related Posts

  • CLINICAL CASES IN MS: A PATIENT WITH MRI LESIONS CONSISTENT WITH MS
    June 27, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF
    June 26, 2025
  • EAN HIGHLIGHTS – TUESDAY, JUNE 24, 2025
    June 24, 2025
  • EAN HIGHLIGHTS – MONDAY, JUNE 23, 2025
    June 23, 2025
  • DMT prescribing in Canada – Part 2
    June 12, 2025
Go back to home page

Browse by Topic

  • CLINICAL CASES IN MS (17)
  • MS (418)
  • EAN 2025 (2)
  • BIOMARKERS IN MS (56)
  • EPILEPSY (36)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • CLINICAL CASES IN MS: A PATIENT WITH MRI LESIONS CONSISTENT WITH MS posted on June 27, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 26, 2025
  • EAN HIGHLIGHTS – TUESDAY, JUNE 24, 2025 posted on June 24, 2025
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions